Novosti v dopolnilnem zdravljenju HER2-pozitivnega raka dojke

Abstract

Keywords

Data

Language:	Slovenian
Year of publishing:	2008
Typology:	1.04 - Professional Article
Organization:	OI - Institute of Oncology
UDC:	616-006
COBISS:	620411
ISSN:	1408-1741
Parent publication:	Onkologija
Views:	2213
Downloads:	530
Average score:	0 (0 votes)
Metadata:

Other data

Secondary language:	English
Secondary title:	Update on Adjuvant Treatment of HER2-Positive Breast Cancer
Secondary abstract:	Although trastuzumab-based regimens have improved both systemic control and overall survival in the patients with HER2-positive breast cancer, in some of these patients, tumor progression occurs despite trastuzumab treatment. New target therapies are searched for these patients. The most promising and, in terms of clinical use, the most developed is lapatinib, a small molecule, tyrosine-kinase inhibitor that targets not only HER2- but also HER1-receptor. It is already used for treating the HER2-positive metastatic breast cancer patients after failure of trastuzumab therapy, but its effectiveness in adjuvant therapy has not been proven yet. ALTTO (Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization) is a randomized phase-three multi-center study of adjuvant lapatinib, trastuzumab, their sequence and their combination in the patients with HER2 positive primary breast cancer.
Secondary keywords:	Breast neoplasms;Drug therapy;Receptor, erbB-2;Antibodies, monoclonal;
URN:	URN:NBN:SI
Pages:	str. 57-60
Volume:	ǂLetn. ǂ12
Issue:	ǂšt. ǂ1
Chronology:	jun. 2008
ID:	10956197